Calidi Biotherapeutics, Inc. (CLDI) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.17 |
| Open | 1.15 |
| Day High | 1.29 |
| Day Low | 1.15 |
| 52-Week High | 27.84 |
| 52-Week Low | 1.05 |
| Volume | 188,849 |
| Average Volume | 258,978 |
| Market Cap | 584,755 |
| PE | -0.02 |
| EPS | -54.3 |
| Moving Average 50 Days | 1.58 |
| Moving Average 200 Days | 7.64 |
| Change | 0.1 |
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
GlobeNewswire Inc.
Mar 10, 2026 12:50 AM GMT
$12 Million of Tranche Warrants Potential Financing Within One Year From ClosingSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the dev
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
GlobeNewswire Inc.
Mar 06, 2026 1:30 PM GMT
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of ClosingSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approac